A 26% slowing of clinical decline on CDR-SB sounds modest until you realize it comes from a drug administered intrathecally just twice a year, targeting a completely different disease pathway than anything currently on the market for early Alzheimer’s. Biogen’s Phase 2 CELIA data, presented at AAIC 2026, show that diranersen, an antisense oligonucleotide targeting MAPT mRNA, reduced CSF total tau by 50 to 65 percent across all studied doses and produced measurable decreases in tau PET signal across every evaluated brain region. That biomarker-to-clinical translation argument has been the central skepticism around tau therapeutics for years. CELIA’s 18-month data make it substantially harder to sustain that skepticism.
The clinical numbers deserve careful reading. The 60 mg dose delivered the strongest signal: 42% slowing on ADAS-Cog13, 50% on MMSE, and that 26% CDR-SB figure. For reference, lecanemab’s Clarity AD trial produced 27% slowing on CDR-SB at 18 months, now the reference point for approved amyloid-targeting agents. Diranersen hit comparable CDR-SB territory with a mechanism that has no amyloid-related imaging abnormality risk, which is a genuine differentiator given that ARIA management remains a real clinical burden. The study did not meet its prespecified primary endpoint, a dose-response relationship on CDR-SB, because higher doses did not produce greater slowing. But the failure of that particular hypothesis doesn’t undermine the efficacy signal; it refines the dose selection conversation for Phase 3. Over 90% of participants who completed the placebo-controlled period chose to enter the extension study, which is a behavioral data point that carries weight.
The mechanism matters strategically. Diranersen targets MAPT mRNA to suppress production of all tau isoforms, reducing both intracellular and extracellular tau protein. That distinguishes it from antibody-based tau approaches that work extracellularly. Biogen licensed diranersen from Ionis Pharmaceuticals in December 2019, and the asset has now cleared Phase 1b and Phase 2 with a consistent safety profile dominated by procedural adverse events from lumbar puncture rather than drug toxicity. The approved landscape already includes lecanemab and donanemab for early Alzheimer’s, both targeting amyloid. A tau-directed agent that complements rather than competes with those drugs on mechanism opens a genuine combination therapy question that Phase 3 will need to be designed to address, at least partially.
The single marker worth tracking as Biogen finalizes Phase 3 design is whether CDR-SB is retained as a co-primary or primary endpoint alongside a functional measure. ADCS-ADL-MCI showed no separation from placebo at 18 months, and regulators have tightened expectations around functional evidence since the lecanemab and donanemab approvals. How Biogen resolves that endpoint tension will determine whether confirmatory data can support a straightforward approval path or require a longer, larger trial.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
